Jan Astermark

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors
    Jan Astermark
    Department of Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Br J Haematol 119:342-7. 2002
  2. ncbi Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors
    J Astermark
    Department for Coagulation Disorders, , Malm, Sweden
    Haemophilia 12:363-71. 2006
  3. ncbi The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
    Jan Astermark
    Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Malmo, Sweden
    Blood 121:1446-54. 2013
  4. ncbi Malignant disease in the haemophilic population: moving towards a management consensus?
    J Astermark
    Centre for Thrombosis and Hemostasis, Skåne University Hospital Malmö, Malmo, Sweden
    Haemophilia 18:664-71. 2012
  5. ncbi Prevention and prediction of inhibitor risk
    J Astermark
    Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Malmo, Sweden
    Haemophilia 18:38-42. 2012
  6. ncbi Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
    Jan Astermark
    Department for Coagulation Disorders, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Blood 108:3739-45. 2006
  7. ncbi A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
    Jan Astermark
    Department for Hematology and Coagulation Disorders, Malmö University Hospital SE 205 02 Malmö, Sweden
    Blood 109:546-51. 2007
  8. ncbi Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:8-13; discussion 13-4. 2006
  9. ncbi Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 13:38-45. 2007
  10. ncbi Inhibitor development
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 14:36-42. 2008

Detail Information

Publications38

  1. ncbi Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors
    Jan Astermark
    Department of Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Br J Haematol 119:342-7. 2002
    ..The characterization of the antibody profile may facilitate an optimal treatment with by-passing agents in severe bleeding events...
  2. ncbi Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors
    J Astermark
    Department for Coagulation Disorders, , Malm, Sweden
    Haemophilia 12:363-71. 2006
    ....
  3. ncbi The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
    Jan Astermark
    Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Malmo, Sweden
    Blood 121:1446-54. 2013
    ..001. Eight of the 53 were significant predictors among the discordant pairs. Results support the complexity of the immune response and encourage further research with the goal of understanding the pathways involved...
  4. ncbi Malignant disease in the haemophilic population: moving towards a management consensus?
    J Astermark
    Centre for Thrombosis and Hemostasis, Skåne University Hospital Malmö, Malmo, Sweden
    Haemophilia 18:664-71. 2012
    ..Ultimately, the aim is to establish consensus guidelines to direct and harmonize future treatment policy for malignant disease in the haemophilic population...
  5. ncbi Prevention and prediction of inhibitor risk
    J Astermark
    Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Malmo, Sweden
    Haemophilia 18:38-42. 2012
    ..By doing so, it may hopefully be possible in the future to prevent the formation of inhibitors in these patients by offering therapeutic options other than the native factor VIII or IX molecule in an inflammatory setting...
  6. ncbi Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
    Jan Astermark
    Department for Coagulation Disorders, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Blood 108:3739-45. 2006
    ..Our data imply that the TNFA -308G>A polymorphism within Hap 2 is a useful marker and potential modulator of the immune response to replacement therapy in patients with hemophilia...
  7. ncbi A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
    Jan Astermark
    Department for Hematology and Coagulation Disorders, Malmö University Hospital SE 205 02 Malmö, Sweden
    Blood 109:546-51. 2007
    ..This trial was registered at www.clinicaltrials.gov as #NCT00166309...
  8. ncbi Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:8-13; discussion 13-4. 2006
    ..Therefore, additional studies are required to quantify the impact of non-genetic factors on the pathophysiologic process of inhibitor development...
  9. ncbi Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 13:38-45. 2007
    ..General recommendations were developed, based on the information provided by the survey. The results clearly indicate the need for well-designed comparative studies to optimize the use of by-passing agents...
  10. ncbi Inhibitor development
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 14:36-42. 2008
    ..In addition, the role of T-regulatory cells in the pathogenicity of inhibitors will be discussed...
  11. ncbi Inhibitor development: patient-determined risk factors
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 16:66-70. 2010
    ....
  12. ncbi Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
    J Astermark
    Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 16:747-66. 2010
    ..Furthermore, there is no evidence to support an association between pregnancy-related issues, breast feeding and treatment-related factors (e.g. route of administration, or use of blood components) and inhibitor development...
  13. ncbi Immune tolerance induction in patients with hemophilia A
    Jan Astermark
    Centre for Thrombosis and Hemostasis, Skåne University Hospital Malmö, SE 205 02 Malmo, Sweden
    Thromb Res 127:S6-9. 2011
    ..Ongoing studies are likely to provide further insight into the role of genetic features and the type of FVIII concentrate on the success rate of ITI...
  14. ncbi Overview of inhibitors
    Jan Astermark
    University of Lund, Malmo, Sweden
    Semin Hematol 43:S3-7. 2006
    ....
  15. ncbi Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia
    J Astermark
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:52-60. 2006
    ..A better understanding of the pathophysiological mechanisms involved will facilitate improvement of therapy in the future, and hopefully provide an opportunity to prevent this complication of treatment...
  16. ncbi Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
    Jan Astermark
    Department for Coagulation Disorders, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Blood 107:3167-72. 2006
    ..5; P < .001). The association was consistent in the subgroup of families with severe hemophilia and inversions. IL10 is the first gene located outside the causative factor VIII gene mutation to be associated with inhibitor development...
  17. ncbi Treatment of the bleeding inhibitor patient
    Jan Astermark
    Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Semin Thromb Hemost 29:77-86. 2003
    ..Available data on these alternative regimens will be discussed with a focus on the mechanisms of action, pharmacokinetics, safety, monitoring, and clinical experience...
  18. ncbi Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma
    Jenny Klintman
    Department for Coagulation Disorders, Lund University, Skane University Hospital, Malmo, Sweden
    Br J Haematol 151:381-6. 2010
    ..In conclusion, the amount of thrombin formed in vitro by adding a by-passing agent, was higher in the presence of FVIII. Our findings support the use of FVIII in by-passing therapy to optimize the haemostatic effect...
  19. ncbi Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life
    Mohammed Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmö Department of Clinical Sciences, Lund University, Malmo, Sweden
    Eur J Haematol 88:329-35. 2012
    ..In the 1950s, Sweden initiated prophylaxis as a lifelong treatment for haemophilia. It was the first country to do so...
  20. ncbi Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro
    J Astermark
    Department for Coagulation Disorders, University Hospital, Malmo, Sweden
    Haemophilia 9:567-72. 2003
    ..Potential clinical implications of the observed differences in inhibitor reactivity are discussed...
  21. ncbi The APC-PCI complex concentration predicts outcome of aortic surgery
    Gunnar Nilsson
    Department of Anaesthesiology and Intensive Care, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Thromb Res 120:237-44. 2007
    ..The purpose of the study was to establish whether the APC-PCI complex can provide information useful for the assessment of outcome after aortic surgery...
  22. ncbi Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis
    M Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 16:495-501. 2010
    ....
  23. ncbi Bone density and health-related quality of life in adult patients with severe haemophilia
    M Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmo, Sweden
    Haemophilia 17:304-11. 2011
    ..Reduced BMD in group B correlated with impaired physical health, which underscores the importance of early onset of adequate prophylactic treatment...
  24. ncbi Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A
    J Klintman
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 16:e210-5. 2010
    ..The nature of these determinants remains to be identified...
  25. ncbi Immune tolerance induction and the treatment of hemophilia. Malmö protocol update
    E Berntorp
    Department for Coagulation Disorders, University of Lund, Malmo University Hospital, Sweden
    Haematologica 85:48-50; discussion 50-1. 2000
    ..We conclude that the Malmö protocol is efficient for induction of immune tolerance but the patients must be selected particularly with regard to inhibitor duration and time of last booster...
  26. ncbi The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
    J Astermark
    Department for Coagulation Disorders, University of Lund, Malmo, Sweden
    Haemophilia 7:267-72. 2001
    ..However, the markers of this predisposition remain to be elucidated and we believe that the MIBS registry will be useful for this purpose...
  27. ncbi Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival
    Gunnar Nilsson
    Department of Anaesthesiology, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Thromb Res 116:15-24. 2005
    ..We therefore studied the usefulness of global haemostatic tests to predict levels of protein C and antithrombin and investigated value of these latter tests in predicting outcome...
  28. ncbi Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis
    Mohamed Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmo, Sweden
    Blood Coagul Fibrinolysis 22:50-5. 2011
    ....
  29. ncbi Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis
    K Strandberg
    Department of Clinical Chemistry, University Hospital, , Lund University, Sweden
    Thromb Haemost 86:1400-8. 2001
    ..The APC-PCI method appears to be particularly useful as a marker for detection of recently developed proximal thrombi...
  30. ncbi Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference
    E Berntorp
    Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:1-7. 2006
    ..Finally, conference participants urged their colleagues to participate in the currently ongoing international trials of ITI...
  31. ncbi The Malmö-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts
    E Berntorp
    Department for Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Haemophilia 4:79-82. 1998
    ..This should not only form a suitable platform for the future development of haemophilia care in Lithuania, but could also serve as an example for liaisons between other haemophilia centres...
  32. ncbi Consensus perspectives on prophylactic therapy for haemophilia: summary statement
    E Berntorp
    Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 9:1-4. 2003
    ..Such studies should include carefully defined cohorts, validated orthopaedic and quality-of-life assessment instruments, and cost-benefit analyses...
  33. ncbi When to start and when to stop primary prophylaxis in patients with severe haemophilia
    J Astermark
    Department for Coagulation Disorders, University of Lund, Malmo University Hospital, Malmo, Sweden
    Haemophilia 9:32-6; discussion 37. 2003
    ..The use of an individualized prophylactic regimen may also improve cost-effectiveness and make the use of this treatment modality more feasible. Studies to further address this issue are warranted...
  34. ncbi Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor
    Katarina Steen Carlsson
    Lund University Centre for Health Economics, LUCHE, Lund, Sweden
    Thromb Haemost 99:1060-7. 2008
    ..The large individual-level variation in reduction of pain supports decisions that consider the individual patient's experience and that accept trade-offs between cost and reduction in pain rather than focusing on cost only...
  35. ncbi From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors
    Edward D Gomperts
    Children s Hospital Los Angeles, Division of Hematology Oncology, 4650 Sunset Blvd, M S 54, Los Angeles, California 90027, USA
    Blood Rev 22:S1-11. 2008
    ....
  36. ncbi Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors
    Christine A Lee
    Haemophilia Centre and Haemostasis Unit, Royal Free and University College Medical School, UCL, London, United Kingdom
    Semin Thromb Hemost 32:10-4. 2006
    ..There is much interest in identifying such genetic and treatment-related factors to help minimize the risk of inhibitor development and improve treatment outcomes...
  37. ncbi The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A
    Jan Astermark
    Department for Coagulation Disorders University Hospital SE 205 02 Malmö, Sweden
    Haematologica 90:924-31. 2005
    ..The objective of this study was to evaluate the mutation type dependent concordance rate of inhibitor formation in siblings...
  38. ncbi Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V
    Falko H Herrmann
    Haematologica 93:1273-5. 2008